<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34470828</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1533-3450</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of the American Society of Nephrology : JASN</Title><ISOAbbreviation>J Am Soc Nephrol</ISOAbbreviation></Journal><ArticleTitle>Kidney Outcomes in Long COVID.</ArticleTitle><Pagination><StartPage>2851</StartPage><EndPage>2862</EndPage><MedlinePgn>2851-2862</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1681/ASN.2021060734</ELocationID><Abstract><AbstractText Label="BACKGROUND">COVID-19 is associated with increased risk of post-acute sequelae involving pulmonary and extrapulmonary organ systems-referred to as long COVID. However, a detailed assessment of kidney outcomes in long COVID is not yet available.</AbstractText><AbstractText Label="METHODS">We built a cohort of 1,726,683 US Veterans identified from March 1, 2020 to March 15, 2021, including 89,216 patients who were 30-day survivors of COVID-19 and 1,637,467 non-infected controls. We examined risks of AKI, eGFR decline, ESKD, and major adverse kidney events (MAKE). MAKE was defined as eGFR decline &#x2265;50%, ESKD, or all-cause mortality. We used inverse probability-weighted survival regression, adjusting for predefined demographic and health characteristics, and algorithmically selected high-dimensional covariates, including diagnoses, medications, and laboratory tests. Linear mixed models characterized intra-individual eGFR trajectory.</AbstractText><AbstractText Label="RESULTS">Beyond the acute illness, 30-day survivors of COVID-19 exhibited a higher risk of AKI (aHR, 1.94; 95% CI, 1.86 to 2.04), eGFR decline &#x2265;30% (aHR, 1.25; 95% CI, 1.14 to 1.37), eGFR decline &#x2265;40% (aHR, 1.44; 95% CI, 1.37 to 1.51), eGFR decline &#x2265;50% (aHR, 1.62; 95% CI, 1.51 to 1.74), ESKD (aHR, 2.96; 95% CI, 2.49 to 3.51), and MAKE (aHR, 1.66; 95% CI, 1.58 to 1.74). Increase in risks of post-acute kidney outcomes was graded according to the severity of the acute infection (whether patients were non-hospitalized, hospitalized, or admitted to intensive care). Compared with non-infected controls, 30-day survivors of COVID-19 exhibited excess eGFR decline (95% CI) of -3.26 (-3.58 to -2.94), -5.20 (-6.24 to -4.16), and -7.69 (-8.27 to -7.12) ml/min per 1.73 m<sup>2</sup> per year, respectively, in non-hospitalized, hospitalized, and those admitted to intensive care during the acute phase of COVID-19 infection.</AbstractText><AbstractText Label="CONCLUSIONS">Patients who survived COVID-19 exhibited increased risk of kidney outcomes in the post-acute phase of the disease. Post-acute COVID-19 care should include attention to kidney disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 by the American Society of Nephrology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bowe</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology Center, Research and Development Service, Veterans Affairs Saint Louis Health Care System, Saint Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, College for Public Health and Social Justice, Saint Louis University, Saint Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Veterans Research and Education Foundation of Saint Louis, Saint Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology Center, Research and Development Service, Veterans Affairs Saint Louis Health Care System, Saint Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, College for Public Health and Social Justice, Saint Louis University, Saint Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Veterans Research and Education Foundation of Saint Louis, Saint Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Evan</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-6132-8374</Identifier><AffiliationInfo><Affiliation>Clinical Epidemiology Center, Research and Development Service, Veterans Affairs Saint Louis Health Care System, Saint Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Saint Louis University School of Medicine, Saint Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Aly</LastName><ForeName>Ziyad</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-2600-0434</Identifier><AffiliationInfo><Affiliation>Clinical Epidemiology Center, Research and Development Service, Veterans Affairs Saint Louis Health Care System, Saint Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Veterans Research and Education Foundation of Saint Louis, Saint Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Washington University School of Medicine, Saint Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nephrology Section, Medicine Service, Veterans Affairs Saint Louis Health Care System, Saint Louis, Missouri.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Public Health, Washington University in Saint Louis, Saint Louis, Missouri.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Soc Nephrol</MedlineTA><NlmUniqueID>9013836</NlmUniqueID><ISSNLinking>1046-6673</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003422" MajorTopicYN="N">Critical Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005919" MajorTopicYN="N">Glomerular Filtration Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007674" MajorTopicYN="N">Kidney Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014728" MajorTopicYN="N">Veterans</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">ESKD</Keyword><Keyword MajorTopicYN="N">ESRD</Keyword><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">acute kidney injury</Keyword><Keyword MajorTopicYN="N">eGFR decline</Keyword><Keyword MajorTopicYN="N">kidney function</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post-acute COVID</Keyword><Keyword MajorTopicYN="N">post-acute sequelae of SARS-CoV-2 infection</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34470828</ArticleId><ArticleId IdType="pmc">PMC8806085</ArticleId><ArticleId IdType="doi">10.1681/ASN.2021060734</ArticleId><ArticleId IdType="pii">00001751-202111000-00019</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Xie Y, Bowe B, Maddukuri G, Al-Aly Z: Comparative evaluation of clinical manifestations and risk of death in patients admitted to hospital with covid-19 and seasonal influenza: Cohort study. BMJ 371: m4677, 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7735416</ArticleId><ArticleId IdType="pubmed">33323357</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Xie Y, Bowe B: High-dimensional characterization of post-acute sequelae of COVID-19. Nature 594: 259&#x2013;264, 2021</Citation><ArticleIdList><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Xie Y, Xian H, Lian M, Al-Aly Z: Geographic variation and US county characteristics associated with rapid kidney function decline. Kidney Int Rep 2: 5&#x2013;17, 2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5678675</ArticleId><ArticleId IdType="pubmed">29142937</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z: Higher blood urea nitrogen is associated with increased risk of incident diabetes mellitus. Kidney Int 93: 741&#x2013;752, 2018</Citation><ArticleIdList><ArticleId IdType="pubmed">29241622</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Xie Y, Yan Y, Al-Aly Z: Burden of cause-specific mortality associated with PM2.5 air pollution in the United States. JAMA Netw Open 2: e1915834, 2019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6902821</ArticleId><ArticleId IdType="pubmed">31747037</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Bowe B, Yan Y, Xian H, Li T, Al-Aly Z: Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: Cohort study. BMJ 365: l1580, 2019</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6538974</ArticleId><ArticleId IdType="pubmed">31147311</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Xie Y, Xian H, Li T, Al-Aly Z: Association between monocyte count and risk of incident CKD and progression to ESRD. CJASN 12: 603&#x2013;613, 2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5383390</ArticleId><ArticleId IdType="pubmed">28348030</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Maddukuri G, Xie Y: Proton pump inhibitors and the kidney: Implications of current evidence for clinical practice and when and how to deprescribe. Am J Kidney Dis 75: 497&#x2013;507, 2020</Citation><ArticleIdList><ArticleId IdType="pubmed">31606235</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Bowe B, Gibson AK, McGill JB, Yan Y, Maddukuri G, et al. : Comparative effectiveness of the sodium-glucose cotransporter 2 inhibitor empagliflozin versus other antihyperglycemics on risk of major adverse kidney events. Diabetes Care 43: 2785&#x2013;2795, 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7576413</ArticleId><ArticleId IdType="pubmed">32912850</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Bowe B, Gibson AK, McGill JB, Maddukuri G, Al-Aly Z: Comparative effectiveness of sodium-glucose cotransporter 2 inhibitors vs sulfonylureas in patients with type 2 diabetes. JAMA Intern Med 181: 1043&#x2013;1053, 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8240007</ArticleId><ArticleId IdType="pubmed">34180939</ArticleId></ArticleIdList></Reference><Reference><Citation>Department of Veterans Affairs : COVID-19: Shared data resource. Available at https://vhacdwdwhweb100.vha.med.va.gov/phenotype/index.php/COVID-19:Shared_Data_Resource#Acknowledgements_COVID-19_Shared_Data_Resource. Accessed May 1, 2020</Citation></Reference><Reference><Citation>Kind AJ, Jencks S, Brock J, Yu M, Bartels C, Ehlenbach W, et al. : Neighborhood socioeconomic disadvantage and 30 day rehospitalizations: An analysis of Medicare data. Ann Intern Med 161: 765, 2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4251560</ArticleId><ArticleId IdType="pubmed">25437404</ArticleId></ArticleIdList></Reference><Reference><Citation>Kind AJH, Buckingham WR: Making neighborhood-disadvantage metrics accessible &#x2014; The neighborhood atlas. N Engl J Med 378: 2456&#x2013;2458, 2018</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6051533</ArticleId><ArticleId IdType="pubmed">29949490</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey AS, Stevens LA: Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: More accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis 55: 622&#x2013;627, 2010</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2846308</ArticleId><ArticleId IdType="pubmed">20338463</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Cai M, Xie Y, Gibson AK, Maddukuri G, Al-Aly Z: Acute kidney injury in a national cohort of hospitalized US veterans with COVID-19. Clin J Am Soc Nephrol 16: 14&#x2013;25, 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7792643</ArticleId><ArticleId IdType="pubmed">33199414</ArticleId></ArticleIdList></Reference><Reference><Citation>Chertow GM, Lazarus JM, Christiansen CL, Cook EF, Hammermeister KE, Grover F, et al. : Preoperative renal risk stratification. Circulation 95: 878&#x2013;884, 1997</Citation><ArticleIdList><ArticleId IdType="pubmed">9054745</ArticleId></ArticleIdList></Reference><Reference><Citation>Klepser DG, Collier DS, Cochran GL: Proton pump inhibitors and acute kidney injury: A nested case-control study. BMC Nephrol 14: 150, 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3717286</ArticleId><ArticleId IdType="pubmed">23865955</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonard CE, Freeman CP, Newcomb CW, Reese PP, Herlim M, Bilker WB, et al. : Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury. Pharmacoepidemiol Drug Saf 21: 1155&#x2013;1172, 2012</Citation><ArticleIdList><ArticleId IdType="pubmed">22887960</ArticleId></ArticleIdList></Reference><Reference><Citation>Okusa MD: The inflammatory cascade in acute ischemic renal failure. Nephron 90: 133&#x2013;138, 2002</Citation><ArticleIdList><ArticleId IdType="pubmed">11818695</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA: High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 20: 512&#x2013;522, 2009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077219</ArticleId><ArticleId IdType="pubmed">19487948</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC: Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28: 3083&#x2013;3107, 2009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3472075</ArticleId><ArticleId IdType="pubmed">19757444</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin DB: Using propensity scores to help design observational studies: Application to the tobacco litigation. Health Serv Outcomes Res Methodol 2: 169&#x2013;188, 2001</Citation></Reference><Reference><Citation>Breslow NE: Discussion of professor Cox&#x2019;s paper. J R Stat Soc B 34: 216&#x2013;217, 1972</Citation></Reference><Reference><Citation>Xie Y, Bowe B, Gibson AK, McGill JB, Maddukuri G, Yan Y, et al. : Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of kidney outcomes: Emulation of a target trial using health care databases. Diabetes Care 43: 2859&#x2013;2869, 2020</Citation><ArticleIdList><ArticleId IdType="pubmed">32938746</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch M, Tchetgen Tchetgen E, Cohen T: Negative controls: A tool for detecting confounding and bias in observational studies. Epidemiology 21: 383&#x2013;388, 2010</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3053408</ArticleId><ArticleId IdType="pubmed">20335814</ArticleId></ArticleIdList></Reference><Reference><Citation>Daugherty SE, Guo Y, Heath K, Dasmarinas MC, Jubilo KG, Samranvedhya J, et al. : SARS-CoV-2 infection and risk of clinical sequelae during the post-acute phase: A retrospective cohort study. BMJ 373: n1098, 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8132065</ArticleId><ArticleId IdType="pubmed">34011492</ArticleId></ArticleIdList></Reference><Reference><Citation>Wickham H: ggplot2: Elegant Graphics for Data Analysis, New York, Springer, 2016</Citation></Reference><Reference><Citation>The Center for Systems Science and Engineering (CSSE) at Johns Hopkins University : The Johns Hopkins Coronavirus Resource Center, COVID-19 Dashboard. 2021. Available at: https://coronavirus.jhu.edu/map.html. Accessed October 4, 2021</Citation></Reference><Reference><Citation>Delorey TM, Ziegler CGK, Heimberg G, Normand R, Yang Y, Segerstolpe &#xc5;, et al. : COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. Nature 595: 107&#x2013;113, 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8919505</ArticleId><ArticleId IdType="pubmed">33915569</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa JD, Brennan PM, Theodoratou E, Poon MTC, Purshouse K, Din FVN, et al. : Distinguishing between direct and indirect consequences of COVID-19. BMJ 369: m2377, 2020</Citation><ArticleIdList><ArticleId IdType="pubmed">32540857</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend E: COVID-19 policies in the UK and consequences for mental health. Lancet Psychiatry 7: 1014&#x2013;1015, 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7561293</ArticleId><ArticleId IdType="pubmed">33069273</ArticleId></ArticleIdList></Reference><Reference><Citation>Knipe D, Evans H, Marchant A, Gunnell D, John A: Mapping population mental health concerns related to COVID-19 and the consequences of physical distancing: A Google trends analysis. Wellcome Open Res 5: 82, 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7331103</ArticleId><ArticleId IdType="pubmed">32671230</ArticleId></ArticleIdList></Reference><Reference><Citation>Raker EJ, Zacher M, Lowe SR: Lessons from Hurricane Katrina for predicting the indirect health consequences of the COVID-19 pandemic. Proc Natl Acad Sci U S A 117: 12595&#x2013;12597, 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7293707</ArticleId><ArticleId IdType="pubmed">32424085</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E: Covid-19: Mental health consequences of pandemic need urgent research, paper advises. BMJ 369: m1515, 2020</Citation><ArticleIdList><ArticleId IdType="pubmed">32299806</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Bowe B, Yan Y, Cai M, Al-Aly Z: County-level contextual characteristics and disparities in life expectancy. Mayo Clin Proc 96: 92&#x2013;104, 2021</Citation><ArticleIdList><ArticleId IdType="pubmed">33413839</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Xie Y, Gibson AK, Cai M, van Donkelaar A, Martin RV, et al. : Ambient fine particulate matter air pollution and the risk of hospitalization among COVID-19 positive individuals: Cohort study. Environ Int 154: 106564, 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8040542</ArticleId><ArticleId IdType="pubmed">33964723</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>